Laura Lyngby Mulloy, DO, FACP, FASN
Professor of Medicine
Vice Chair for Clinical Affairs &
Chief Section of Nephrology, Hypertension and Transplantation Medicine
Georgia Regents University
Nephrology BA 9413
1120 15th Street
Augusta, GA, USA
Dr. Mulloy serves as Vice-Chair, Clinical Affairs and Faculty Development, of the Department of Medicine and Section Chief of Nephrology, Hypertension and Transplant Medicine. She is a graduate of Michigan State University and Chicago College of Osteopathic Medicine. She completed a rotating internship at the Dallas/Ft. Worth Medical Center, followed by internal medicine training at Texas Tech University Health Sciences Center and the Yale University affiliated Waterbury Hospital Health Center. She then completed her nephrology fellowship at the Medical College of Georgia prior to joining the faculty in 1990. Dr. Mulloy is a fellow and member of the American Society of Nephrology, the National Kidney Foundation, and is on the American Society of Transplantation Fellowship Accreditation Committee. She serves on the Medical Advisory Board for the National Kidney Foundation of Georgia. Her research interests include clinical investigation of immunosuppressive therapies for renal transplantation, and hypertension in chronic kidney disease. She is the Co-PI for the NIH sponsored SPRINT protocol for evaluation blood pressure in patients with chronic kidney disease.
Dr. Mulloy directed the MCG nephrology fellowship training program from 1991-2007 and served as Section Chief since 1998. She was appointed Interim Chair for the Department of Medicine from 2006-2008 where she implemented a successful a mentoring and development program for junior faculty that continues to flourish. Program participants have had more scholarly activity, and the program has enhanced academic and promotional activity of junior and senior faculty. Dr. Mulloy is active in medical education at multiple levels, serving as course director for the James B. Hudson Nephrology Update, and the Alan Roberts Mini-medical School conference, and Co-Director for the Primacy and Family Practice Symposium & Internal Medicine Update courses for GRU.
Dr. Mulloy is very active in MCG Faculty Governance, serving on the: Faculty Senate, the MCG Executive Committee, the MCG Promotion and Tenure Committee, and the MCG Faculty Development Committees. She is the current Chair of the Georgia Regents University Faculty Senate.
Dr. Mulloy maintains an active clinical practice in the care of renal transplant recipients and those with chronic kidney disease. She is a certified Hypertension Specialist & treats patients with resistant hypertension. She attends on the GRU renal inpatient medical service as well as staff nephrology/ transplant clinics at the Charlie Norwood Veterans Affairs Medical Center. She is the Medical Director for the GRU Executive Wellness Program, which provides concierge/customized medical care for patients in a boutique setting.
Her research interests include: Kidney Transplantation, Immunosuppressive Agents, Cyclosporine Graft Rejection, Tacrolimus, Graft Survival, Patient Compliance, Mycophenolic Acid.
AWARDS AND HONORS
• (1995), Attending of the Year Department of Medicine, Medical College of Georgia
• (1997), Attending of the Year Department of Medicine, Medical College of Georgia
•(1997), Faculty Excellence in Teaching Award Department of Medicine, Medical College of Georgia
• (1998), Faculty Excellence in Teaching Award Department of Medicine, Medical College of Georgia
• (2003), Educator of the Year Award
Medical College of Georgia Class of 2003
• (2005), Whos Who Among American Physicians
• (2008), Hospital Appreciation and Recognition Award
• (2009), SOM Exemplary Teacher Award
• (2009), Outstanding Basic Science Teaching Department Award (Microbiology/Infectious Diseases) Medical College of Georgia Class of 2009
• (2009), Educator of the Year Medical College of Georgia Class of 2009
• (2009), Exemplary Teaching Award for Medical Student Teaching
• (2009), Exemplary Teaching Award for Medical Student Teaching National Medical Honor Society, Alpha Omega Alpha Best Doctors in Augusta, June/July Augusta Magazine
• (2010), Outstanding Faulty Award Fellow American Society of Nephrology
• (2011), Family Choice Award
• (2011), Outstanding Faculty Award for the MCG Faculty Senate
• (2011), SOM Exemplary Teacher Award
• (2012), GHSU Academy of Educators
• (2012), ELL Scholar
• (2012), Educator of the Year Award Medical College of Georgia Class of 2013
• (2014), Regional Top Doctors List
PUBLICATIONS IN REFEREED JOURNALS
1. Burdick JR, Lyngby LK, Tarr RS. Isolation of Salmonella from laboratory-housed iguanid lizards. J of Herpetal. 1984; (18): 88-91.
2. Mulloy LL, Caruana RJ, Steele JCH, Wynn JJ. Polymicrobial bacteremia in chronic hemodialysis patients. Southern Medical Journal. 1991.
3. Mulloy AL, Mulloy LL, Weinstein RS. Hypercalcemia due to hard water during home hemodialysis. South. Med. J. 1992; 85: 1131-1133.
4. Epstein A, Beall A, Wynn J, Mulloy L, Brophy CM. Cyclosporine, but not FK506, selectively induces renal and coronary artery smooth muscle contraction. Surgery. 1998; 123: 456-460. doi: http://dx.doi.org/10.1016/S0039-6060(98)70168-0
5. Wynn JJ, Barnett JE, Mulloy LL, Jagadeesan M, Humphries AL. Living-related kidney donation. The Journal of the Medical Association of Georgia. 1998; 87: 80-82.
6. Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind randomized, Multicenter, Phase III clinical trial of thymoglobulin versus ATGAM in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998; 66: 29-37.
7. McCune TR, Thacker LR, Peters TG, et al. Effects of Tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation. 1998; 65: 87-92.
8. Kahan BD, Rajagopalan PR, Hall M. For the United States Simulect Renal Study Group. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukine-2-receptor monoclonal antibody. Transplantation. 1999; 67: 276-284.
9. Woodle ES, First MR, Gaber AO, et al. 12-month outcome of the double-blind, randomized multicenter rejection trial of thymoglobulin vs Atgam in renal transplants. Graft. 1999; 2(1): 24-27.
10. Mulloy LL, Wright F, Hall ML, Moore M. Simulect (Basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors. Transplantation Proceedings. 1999; 31: 1210-1213. doi: http://dx.doi.org/10.1016/S0041-1345(98)02094-6
11. Gaber LW, Moore LW, Gaber AO, Tesi RJ, Meyer J, Schroeder TJ. For the US Multicenter Thymoglobulin Study Group. Correlation of histology in clinical rejection reversal: A. Thymoglobulin Multicenter Trial report. Kidney International. 1999; 55: 2415-2422.
12. Kovarik JM, Kahan BD, Rajagopalan PR, et al. On behalf of the US Simulect Renal Transplant Study Group. Population pharmacokinetics and exposure-response relationships for basiliximab in renal transplantation. Transplantation. 1999; 68(9): 1288-1294.
13. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus in combination with azathioprine or mycophenolate mofetil versus cyclosporine with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation . 2000; 69: 834-841.
14. Chisholm M, Vollenweider L, Mulloy L, Wynn J, Wade B, DiPiro J. Cost-benefit analysis of a clinical pharmacist-managed medication assistance program in a renal transplant clinic. Transplantation. 2000; 14: 304-307. doi: 10.1034/j.1399-0012.2000.140405.x
15. Chisholm M, Vollenweider L, Mulloy L, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation. 2000; 70: 1240-1244.
16. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of prograf + mycophenolate mofetil or azathioprine vs neoral + mycophenolate mofetil after cadaveric kidney transplantation: Results at two years. Transplantation. 2000; 72: 245-250.
17. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients compliance with immunosuppressive medications. Clinical Transplantation. 2001; 15 (5): 330-336. doi: 10.1034/j.1399-0012.2001.150505.x
18. Lightfoot BO, Mulloy LL, Jagadeesan M, Ahmed S, Balachandran S. AceI-Induced Attenuation of Platelet Timp-1 Production in Renal Allograph Recipients. possible Impact on Erythropoiesis. Transplantation Proceedings. 2002; 34(5): 1806-1807. doi: http://dx.doi.org/10.1016/S0041-1345(02)03085-3
19. Chisholm MA, Mulloy LL, Jagadeesan M, Martin BC, DiPiro JT. Effect of clinical pharmacy services on the blood pressure of African-American renal transplant patients. Ethnicity & Disease. 2002; 12(3): 392-397.
20. Lawen JG, Davies EA, Mourad G, et al. Simulect International Study Group. Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with myconphenolate mofetil-containing triple therapy. Renal transplantation. 2005; 75(1): 37-43.
21. Chisholm MA, Mulloy LL, Jagadessan M, DiPiro JT. Codministration of Tacrolimus with Anti-Acid Drugs. Transplantation. 2003; 76: 655-666.
22. Prisant LM, Loebl DH, Mulloy LL. Scleroderma Renal Crisis. Journal of Clinical Hypertension. 2002; 176(5(2)): 168-170. dio: 10.1007/s12016-009-8191-5.
23. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 2003; 75(12): 2048-2053.
24. Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of an immunosuppressant therapy adherence barrier instrument. Nephrology Dialysis Transplantation. 2005; 20(1): 181-188. doi: 10.1093/ndt/gfh576
25. Chisholm MA, Lance CE, Mulloy LL. Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. American Journal of Health System Pharmacy. 2005; 62(17): 1775-1781. dio: 10.2146/ajhp040541
26. Chisholm MA, Lance CE, Williamson GM, Mulloy LL. Development and validation of the immunosuppressant therapy adherence instrument (ITAS). Patient Education and Counseling. 2005; 59(1): 13-20. doi: http://dx.doi.org/10.1016/j.pec.2004.09.003
27. Prisant LM, Szerlip HM, Mulloy LL. Fibromuscular dysplasia: an uncommon cause of secondary hypertension. Journal of Clinical Hypertension. 2006; 8(12): 894-898.
28. Shihab FS, Waid T, Conti D, et al. Conversion from Cyclosporine to Tacrolimus in Patients at Risk for Chronic Renal Alograft Failure: 60-Month Results of the CRAF Study. Transplantation. 2008; 85(9): 1261-1269. doi: 10.1097/TP.0b013e31816b4388.
29. Juan Wu, Zhang W, et al. Isoforms of human leukocyte antigen-G and their inhibitory receptors in human kidney allograft acceptance. Human Immunology. 2009; 70(12): 988-994. doi: 10.1016/j.humimm.2009.07.023
30. Hutchinson AJ, Barnett ME, Krause RJ, et al. Lanthanum carbonate treatment for up to 6 years is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrology. 2009; 71: 286-295.